How Ultra-Thin Technology Is Changing the Possibilities for Neurological Medicine

Some of the most consequential advances in medical technology begin with a deceptively simple engineering question: What if an essential device could be made dramatically smaller, thinner, or more flexible without sacrificing its ability to perform?

In neurological medicine, where physicians must navigate extraordinarily delicate tissue and identify abnormalities with remarkable precision, the answer can have implications far beyond the dimensions of the device itself. A thinner electrode may offer new approaches to monitoring brain activity. A more versatile instrument may allow diagnostic and therapeutic functions to be combined. And an improved method of reaching targeted tissue could eventually influence how treatments are delivered.

These possibilities are helping shape the next generation of neurological technology, including innovations developed by NeuroOne Medical Technologies Corporation, a Minnesota-based medical-device company applying thin-film engineering to neurological monitoring, targeted ablation, and investigational drug-delivery systems.

Its approach reflects a broader trend in medical technology: rather than simply adding more equipment to increasingly complex procedures, developers are finding ways to make individual devices more adaptable and capable of performing multiple functions.

The Engineering Advantage of Going Thinner

Neurological electrodes have long played an essential role in understanding the brain’s electrical activity. For patients with certain forms of epilepsy, physicians may need to place electrodes directly on or within brain tissue to identify the regions responsible for seizures.

Traditional cortical electrodes commonly use silicone-based materials that provide electrical insulation and support the contacts used to record neural signals. These devices have served medicine for decades, but their thickness and flexibility can influence how they conform to the brain’s surface.

NeuroOne has approached electrode design through thin-film manufacturing techniques intended to reduce the physical profile of the device while preserving its diagnostic capabilities.

Its Evo Cortical electrodes measure approximately 0.08 millimeters thick, or 80 microns, making them about seven times thinner than conventional silicone electrodes, according to company specifications.

That’s thinner than the diameter of a typical human hair.

The significance lies in the relationship between the electrode and the tissue it contacts. A thinner, more flexible device can be designed to follow the contours of the brain’s surface more closely, potentially improving its ability to conform to anatomical structures while reducing the amount of material introduced into a sensitive environment.

The underlying engineering also provides opportunities to rethink how electrodes are manufactured and adapted for different applications.

But perhaps the most interesting development is that NeuroOne has extended its technology beyond recording electrical activity.

When One Device Can Perform Two Functions

The conventional process of diagnosing and treating drug-resistant epilepsy can involve multiple stages.

Physicians may first implant electrodes to record brain activity and identify where seizures originate. Once the affected region has been located, a separate procedure may be considered to treat the tissue responsible.

NeuroOne’s FDA-cleared OneRF Brain Ablation System introduces a different approach by allowing compatible implanted electrodes to perform both diagnostic recording and targeted radiofrequency ablation.

The electrodes can first help physicians identify abnormal electrical activity. They can then deliver controlled radiofrequency energy to create small, targeted lesions in selected brain tissue.

The system incorporates temperature monitoring to help physicians control the ablation process.

From an engineering perspective, the distinction is important because it brings diagnostic and therapeutic capabilities together through a single implanted device.

In appropriate cases, physicians may be able to complete the diagnostic and therapeutic stages during one hospitalization without removing the electrode and introducing a separate treatment instrument.

That does not eliminate the need for electrode implantation or make the entire procedure noninvasive. It does, however, create the possibility of reducing additional surgical steps for selected patients.

And the practical implications become clearer when looking at how the technology has already been used.

A Different Way to Deliver Neurological Treatment

In 2024, physicians at University Hospitals in Cleveland used NeuroOne’s OneRF technology to treat a patient with complex epilepsy.

The medical team performed 44 targeted ablations over two days using electrodes that had already been implanted for neurological monitoring.

Rather than transporting the patient to the operating room for additional surgical procedures, physicians performed the ablations at the bedside.

The case demonstrated how a device originally placed for diagnostic purposes could subsequently serve as a therapeutic instrument.

Physicians reported improvements in seizure frequency and aspects of the patient’s mood and memory, although longer-term outcomes remained under evaluation.

While a single clinical case cannot establish the effectiveness of a technology across a broader patient population, it illustrates the potential operational advantages of combining functions that previously might have required separate interventions.

For hospitals, the ability to perform certain treatments using existing implanted devices could eventually influence procedural workflows, equipment requirements, and the use of operating room resources.

For medical-device engineers, it provides another example of how multifunctionality can become as important as miniaturization.

Expanding the Technology Into New Applications

The same underlying expertise in targeted radiofrequency energy delivery has also enabled NeuroOne to develop technology for another neurological condition: trigeminal neuralgia.

The disorder affects the trigeminal nerve and can cause sudden episodes of severe facial pain, sometimes triggered by routine activities such as eating or speaking.

NeuroOne’s separately FDA-cleared OneRF Trigeminal Nerve Ablation System is designed to deliver targeted radiofrequency treatment to selected nerve tissue.

One of its technological distinctions is the ability to map and treat different nerve distributions without repeatedly repositioning the probe, potentially simplifying portions of the procedure.

In October 2026, NeuroOne announced peer-reviewed findings involving 15 patients treated with the system. Fourteen experienced immediate freedom from pain, while the remaining patient became pain-free approximately one week later. At an average follow-up of six months, all 15 had achieved favorable clinical outcomes, although some continued taking medication.

The study was small and retrospective, and additional research will be needed to evaluate long-term effectiveness and outcomes across larger patient populations.

Nevertheless, the application illustrates how an engineering capability developed for one neurological purpose can be adapted to address another clinical challenge.

Rather than treating each medical condition as requiring an entirely unrelated technological solution, companies are increasingly exploring how established platforms can support multiple applications.

Beyond Electrical Recording and Ablation

Another potential direction for neurological technology involves delivering therapeutic agents directly into targeted areas of the brain.

The blood-brain barrier is one of the body’s most important protective systems, but it also limits the ability of many medications to reach brain tissue.

For researchers investigating brain tumors and certain neurological diseases, localized drug delivery remains an important area of scientific development.

NeuroOne’s investigational StereoCED platform is designed to combine targeted delivery of therapeutic agents with neurological electrical recording capabilities.

The concept builds upon the company’s expertise in accessing and monitoring specific areas of brain tissue, while introducing a potential additional function: delivering experimental treatments directly to the intended location.

In October 2026, NeuroOne announced its first pharmaceutical-industry purchase order involving StereoCED, supporting a planned preclinical research program with a major global pharmaceutical company.

The research is expected to explore the platform’s combined drug-delivery and monitoring capabilities in a large-animal model.

StereoCED remains investigational and has not established clinical effectiveness or received clearance for commercial therapeutic use.

Still, the research illustrates how thin-film engineering and neurological access technologies may eventually contribute to applications beyond traditional medical-device procedures.

The Broader Future of Multifunctional Medical Devices

The evolution of neurological electrodes reflects a larger shift taking place across medical technology.

Miniaturization, flexible materials, precision manufacturing, and integrated device functions are changing how engineers approach longstanding clinical challenges.

Instead of developing instruments that perform only one task, researchers are increasingly investigating technologies capable of gathering information, delivering treatment, and potentially monitoring the response through a more integrated system.

For NeuroOne, the progression from thin-film electrodes to targeted ablation and investigational drug delivery illustrates how a specialized technological foundation can support a wider range of medical applications.

Each advancement brings its own technical, clinical, and regulatory challenges. Reducing device dimensions does not automatically improve patient outcomes, and combining multiple functions requires careful evaluation of safety, effectiveness, and practical clinical use.

But the direction is compelling.

As medical technology becomes more precise, the relationship between a device’s physical size and its capabilities may continue to change. Instruments that once served primarily as diagnostic tools may increasingly become part of the treatment process itself.

And in neurological medicine, where precision is essential and unnecessary procedural complexity can carry significant consequences, the ability to accomplish more with smaller, more adaptable devices could become an increasingly important area of innovation.

Sometimes, the biggest opportunities in medical engineering begin by making something remarkably thin.

Sources and References: NeuroOne Medical Technologies Corporation, Evo Cortical Electrode specifications and technical information (nmtc1.com); U.S. Food and Drug Administration, OneRF Ablation System 510(k) clearance K231675; University Hospitals Cleveland Medical Center, December 9, 2024, clinical report involving bedside neurological ablation; NeuroOne 2024 Form 10-K and company materials describing diagnostic and therapeutic applications; October 29, 2026, peer-reviewed OneRF Trigeminal Nerve Ablation findings; October 22, 2026, announcement of the StereoCED pharmaceutical research program; and NeuroOne research materials concerning thin-film electrode technology and investigational drug delivery.